NCT05753059View on ClinicalTrials.gov

Mechanisms of Diuretic Resistance in Heart Failure, Aim 2

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Heart Failure
Interventions
DRUG

Placebo

This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, added to bumetanide on Days 0, 7, 14 and 21

DRUG

Amiloride

This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21

DRUG

Bendroflumethiazide

This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of bendroflumethiazide/placebo and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21

Trial Locations (1)

06510

RECRUITING

Yale University, New Haven

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Yale University

OTHER